CARB-X

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

GangaGen, Inc. is a clinical-stage biotechnology company based in Palo Alto, California, with research and development operations in Bangalore, India. Founded in 2000, the company specializes in discovering and developing novel therapeutic proteins aimed at treating infectious diseases, particularly those caused by antibiotic-resistant bacteria. Its lead product, StaphTAME, is a recombinant protein designed for the topical prevention and treatment of staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA). GangaGen employs a proprietary platform to create highly specific therapeutic proteins known as ectolysins, which target clinically significant bacterial strains, offering innovative solutions for serious infections such as pneumonia and neonatal sepsis caused by multidrug-resistant organisms.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Helmholtz Institute for Pharmaceutical Research Saarland is a research institute that focuses on the development of pharmaceutical and natural product-based research for novel anti-infectives.

GlyProVac is focused on developing a glycoprotein-based vaccine aimed at preventing infections caused by Enterotoxigenic Escherichia coli (ETEC). Utilizing its proprietary BEMAP technology, the company identifies various O-linked protein glycosylations, which serve as potential targets for antimicrobial intervention. This innovative approach aims to enhance immune responses in individuals, thereby reducing the risk of ETEC infections. Through its research and development efforts, GlyProVac seeks to contribute to public health by addressing a significant cause of gastrointestinal disease, particularly in vulnerable populations.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

Syntiron’s antigen discovery and purification technology targets the bacterial iron transport proteins that are critical for causing an infection.

Intravacc is a research and development organization with over 100 years of experience in vaccinology. The company specializes in the independent development of vaccines, taking them from initial concepts through to clinical phase I and II studies. Intravacc has a diverse product pipeline and holds various patents, reflecting its commitment to innovation in vaccine technology. Among its projects, the organization is developing vaccines to prevent infections caused by Neisseria gonorrhoeae, aiming to assist healthcare practitioners in treating patients effectively. Intravacc offers comprehensive solutions to optimize vaccine processes and technologies, facilitating the transition from discovery to late-stage clinical studies.

The Doherty Institute is a prominent research and education facility dedicated to advancing global health through the study and management of infectious diseases. It focuses on discovery research aimed at the prevention, treatment, and cure of these diseases. The institute offers a range of educational programs, including undergraduate and postgraduate courses, as well as professional development opportunities, aligning with its research themes in immunology, viral infectious diseases, host-pathogen interactions, antimicrobial resistance, public health, epidemiology, and genomics. By integrating research and clinical services, the Doherty Institute plays a crucial role in developing innovative strategies to combat infectious diseases and improve health outcomes worldwide.

GangaGen, Inc. is a clinical-stage biotechnology company based in Palo Alto, California, with research and development operations in Bangalore, India. Founded in 2000, the company specializes in discovering and developing novel therapeutic proteins aimed at treating infectious diseases, particularly those caused by antibiotic-resistant bacteria. Its lead product, StaphTAME, is a recombinant protein designed for the topical prevention and treatment of staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA). GangaGen employs a proprietary platform to create highly specific therapeutic proteins known as ectolysins, which target clinically significant bacterial strains, offering innovative solutions for serious infections such as pneumonia and neonatal sepsis caused by multidrug-resistant organisms.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Avails Medical, Inc. is an in vitro diagnostics company based in Menlo Park, California, focused on addressing antibiotic resistance and healthcare-associated infections. Founded in 2013, the company has developed an innovative electronic biosensor technology that enables rapid and accurate detection of infections across various bodily fluids. This technology provides real-time information on antibiotic sensitivity and resistance, allowing healthcare providers to optimize treatment at the point of prescription. Avails Medical's flagship product, eQuant, is a compact instrument that integrates a cuvette with an electrical sensor to analyze diluted blood samples. By facilitating diagnostic-guided therapy, the company's platform significantly reduces the time to treatment from days to minutes, thereby transforming the infection detection landscape and addressing a critical global health challenge.

Clarametyx Biosciences, Inc. is a biotechnology company based in Columbus, Ohio, focused on developing targeted and immune-enabling biologic therapies to address persistent infections linked to biofilms. Founded in 2020, the company utilizes a novel technology platform designed to penetrate the protective layers surrounding bacteria, facilitating immune responses and enhancing the effectiveness of antibiotic interventions. Among its key developments is CMTX-001, a humanized monoclonal antibody currently in preclinical stages aimed at treating hospital-acquired pneumonia. Clarametyx's innovative approach seeks to combat life-threatening infections while addressing the growing concerns of antibiotic resistance.

Debiopharm Group is a biopharmaceutical development specialist based in Lausanne, Switzerland, focusing on in-licensing promising biologics and small molecule drug candidates for global registration. The group aims to maximize the commercial potential of its products through out-licensing agreements with pharmaceutical partners for sales and marketing. It operates multiple investment arms, including the Debiopharm Innovation Fund, which invests in early-stage companies within the biotechnology, diagnostics, and digital health sectors, focusing on smart data and biomarker development. This fund typically invests between $1 million and $10 million, seeking minority stakes and board representation in its portfolio companies. Additionally, Debiopharm Investment engages in private equity and real estate investments, targeting mature companies in IT security and renewable sectors, as well as residential and commercial properties primarily in Western Europe. With a commitment to long-term investments and active involvement in corporate governance, Debiopharm Group drives its portfolio companies toward successful market exits.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company based in Tucson, Arizona, focused on addressing serious infections and the challenge of drug-resistant organisms. Established in 1982, the company specializes in the rapid identification and antibiotic susceptibility testing of infectious pathogens through its innovative Accelerate Pheno system. This platform is designed to analyze samples for both gram-positive and gram-negative organisms, as well as yeast, delivering results significantly faster than traditional methods. By utilizing a proprietary culture-free process that combines genomic and phenotypic detection technologies, the system can provide results from a positive blood culture sample in approximately five hours. Accelerate Diagnostics primarily serves markets in the United States, Europe, and the Middle East, aiming to improve patient outcomes by facilitating timely and accurate diagnosis of healthcare-associated infections.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.

GenomeKey is an early-phase company focused on advancing healthcare through innovative genomic technology and artificial intelligence. It has developed a diagnostic platform that utilizes DNA sequencing and machine learning to rapidly identify bacterial presence, species, and antimicrobial resistance, reducing diagnostic time from days to hours. This automated, lightweight, and scalable system integrates seamlessly into existing hospital ecosystems, allowing microbiologists to effectively interpret the data and gain insights into microbial resistance by identifying new genomic regions. Through its cutting-edge approach, GenomeKey addresses critical challenges in healthcare diagnostics.

Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Novel Microdevices, LLC is focused on developing handheld devices for molecular diagnostics, specifically through its product, NOVEL DX. This innovative device utilizes microfluidics technology to analyze raw biological samples directly at the point of care, providing results in just 30 minutes. By enabling healthcare professionals to achieve lab-quality results without the need for a traditional laboratory setting, the device addresses various sectors including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture. Founded in 2014 by Andrea Pais, Novel Microdevices is headquartered in Baltimore, Maryland.

The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. Uniquely it focuses both on diseases of humans and livestock and tests new vaccine approaches in parallel in different species. A major theme is translational research involving the rapid early-stage development and assessment of new vaccines in clinical trials. The Institute comprises the research activities of over 30 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. Together the Institute Investigators comprise one of the largest non-profit sector research and development activities in vaccinology. Jenner Institute Investigators, through the support of many funders, are developing new vaccine candidates against major global infectious diseases. New vaccines against malaria, tuberculosis and HIV are currently in field trials in the developing world. Research is also underway on livestock vaccines against foot and mouth disease, avian influenza, bovine tuberculosis and other major causes of economic loss.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

GlaxoSmithKline is a global healthcare company based in the United Kingdom, dedicated to improving health outcomes by providing innovative and high-quality healthcare products. The company operates through three main divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Its Pharmaceuticals unit features a diverse range of innovative and established medicines, with a strong focus on respiratory diseases and HIV. The research and development efforts emphasize immunology, genetics, and advanced technologies. GSK's Vaccines division is notable for its extensive portfolio and innovative pipeline, delivering over two million vaccine doses daily to populations in over 160 countries. The Consumer Healthcare segment focuses on developing and marketing a variety of well-regarded brands in categories such as pain relief, respiratory health, oral health, digestive health, nutrition, and skin health. Through its commitment to scientific advancement and public health, GlaxoSmithKline seeks to enable people to lead healthier lives.

The University of Queensland (UQ), established in 1909 and located in Brisbane, Australia, is a prominent public research university known for its commitment to knowledge leadership and quality education. It consistently ranks among the world's top universities and has received more national teaching awards than any other Australian institution. UQ serves approximately 53,600 students across its three campuses, offering a wide range of degree programs, including associate, bachelor, master, and doctoral degrees. The university aims to empower its students to drive positive societal change through innovative research and teaching excellence.

Institute for Molecular Bioscience is a research institute at The University of Queensland.

Avails Medical, Inc. is an in vitro diagnostics company based in Menlo Park, California, focused on addressing antibiotic resistance and healthcare-associated infections. Founded in 2013, the company has developed an innovative electronic biosensor technology that enables rapid and accurate detection of infections across various bodily fluids. This technology provides real-time information on antibiotic sensitivity and resistance, allowing healthcare providers to optimize treatment at the point of prescription. Avails Medical's flagship product, eQuant, is a compact instrument that integrates a cuvette with an electrical sensor to analyze diluted blood samples. By facilitating diagnostic-guided therapy, the company's platform significantly reduces the time to treatment from days to minutes, thereby transforming the infection detection landscape and addressing a critical global health challenge.

Lumen Bioscience, Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutic biologics for oral delivery. Founded in 2017, the company utilizes Spirulina, a blue-green algae, as a platform for the industrial-scale production of high-value molecules. Lumen Bioscience aims to create biologic drugs more efficiently than traditional methods, offering potential advancements in speed, scalability, and cost-effectiveness. The company serves various industries, including food, cosmetics, and healthcare, and is engaged in areas such as synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology. By addressing prevalent diseases that currently lack effective treatments, Lumen Bioscience seeks to provide clinicians with innovative therapeutic options.

Spexis AG is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs and antibiotics to address severe or life-threatening diseases. Founded in 1996, the company focuses on addressing high unmet medical needs, particularly in the areas of antibiotic resistance and respiratory diseases. Spexis's lead product, murepavadin, is currently in Phase III development targeting Pseudomonas aeruginosa, a pathogen identified as a critical priority by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of innovative therapeutics in the respiratory domain.

The Helmholtz Centre for Infection Research applies basic research findings to medical applications. The company's goal is to lay the groundwork for new diagnostic tools, drugs, and therapies for infectious diseases. It researches pathogens that are medically important or can be used as models for infection research. Understanding these mechanisms will aid in the development of new drugs and vaccines to combat infectious diseases.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Clarametyx Biosciences, Inc. is a biotechnology company based in Columbus, Ohio, focused on developing targeted and immune-enabling biologic therapies to address persistent infections linked to biofilms. Founded in 2020, the company utilizes a novel technology platform designed to penetrate the protective layers surrounding bacteria, facilitating immune responses and enhancing the effectiveness of antibiotic interventions. Among its key developments is CMTX-001, a humanized monoclonal antibody currently in preclinical stages aimed at treating hospital-acquired pneumonia. Clarametyx's innovative approach seeks to combat life-threatening infections while addressing the growing concerns of antibiotic resistance.

Locus Biosciences is a biotechnology company focused on developing a CRISPR-engineered precision antibacterial platform aimed at transforming the treatment of bacterial diseases. The company integrates the antibacterial capabilities of CRISPR-Cas3 technology with the effective and safe delivery of bacteriophages, which are viruses that specifically target bacteria. This innovative approach allows for rapid initiation of treatment by physicians, leading to improved medical outcomes for patients. Through its advanced platform, Locus Biosciences seeks to address the challenges posed by pathogenic bacteria in a precise and targeted manner.

Cellics Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2014. The company specializes in developing innovative biomimetic nanomedicines aimed at addressing serious diseases with significant unmet medical needs. Its primary focus includes autoimmune and inflammatory diseases, as well as challenging infectious diseases. Cellics is advancing its lead product candidate, CTI-005, which is intended for the treatment of bacterial pneumonia and is on track for human clinical trials. In addition to its therapeutic efforts, the company is also engaged in creating best-in-class vaccines for various diseases. Through its proprietary nanosponge technology, Cellics aims to enhance treatment options for conditions caused by virulent factors and animal venoms, ultimately striving to improve patient health and outcomes.

Spexis AG is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs and antibiotics to address severe or life-threatening diseases. Founded in 1996, the company focuses on addressing high unmet medical needs, particularly in the areas of antibiotic resistance and respiratory diseases. Spexis's lead product, murepavadin, is currently in Phase III development targeting Pseudomonas aeruginosa, a pathogen identified as a critical priority by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of innovative therapeutics in the respiratory domain.

GangaGen, Inc. is a clinical-stage biotechnology company based in Palo Alto, California, with research and development operations in Bangalore, India. Founded in 2000, the company specializes in discovering and developing novel therapeutic proteins aimed at treating infectious diseases, particularly those caused by antibiotic-resistant bacteria. Its lead product, StaphTAME, is a recombinant protein designed for the topical prevention and treatment of staphylococcal infections, including methicillin-resistant Staphylococcus aureus (MRSA). GangaGen employs a proprietary platform to create highly specific therapeutic proteins known as ectolysins, which target clinically significant bacterial strains, offering innovative solutions for serious infections such as pneumonia and neonatal sepsis caused by multidrug-resistant organisms.

GlaxoSmithKline is a global healthcare company based in the United Kingdom, dedicated to improving health outcomes by providing innovative and high-quality healthcare products. The company operates through three main divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Its Pharmaceuticals unit features a diverse range of innovative and established medicines, with a strong focus on respiratory diseases and HIV. The research and development efforts emphasize immunology, genetics, and advanced technologies. GSK's Vaccines division is notable for its extensive portfolio and innovative pipeline, delivering over two million vaccine doses daily to populations in over 160 countries. The Consumer Healthcare segment focuses on developing and marketing a variety of well-regarded brands in categories such as pain relief, respiratory health, oral health, digestive health, nutrition, and skin health. Through its commitment to scientific advancement and public health, GlaxoSmithKline seeks to enable people to lead healthier lives.

Mutabilis SAS is a biopharmaceutical company based in Romainville, France, founded in 2001. The company specializes in the research and development of innovative anti-infective treatments aimed at addressing the challenges posed by multidrug-resistant Gram-negative bacterial infections. Mutabilis is engaged in discovering new therapeutic targets and developing a novel class of drugs to combat severe and nosocomial infections. Its portfolio includes antibacterials, vaccines, and other anti-infective agents, with a focus on applications in human health, immunology, allergology, hematology, and infectiology. As of June 2009, Mutabilis operates as a subsidiary of Pharma Omnium International SAS.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

ContraFect Corporation is a clinical-stage biotechnology firm based in Yonkers, New York, specializing in the development of therapeutic proteins and antibodies for the treatment of life-threatening, drug-resistant infectious diseases. The company's lead candidate, CF-301, is a novel lysin currently undergoing Phase III clinical trials for staphylococcus aureus bacteremia, including endocarditis. ContraFect is also advancing CF-296, an engineered lysin targeting invasive staphylococcal infections, and CF-370, an investigational therapy in preclinical stages aimed at treating infections caused by pseudomonas aeruginosa. The company has a research collaboration with The Rockefeller University to identify novel lysin candidates targeting gram-negative pathogens. Additionally, ContraFect has initiated an expanded access program for exebacase, intended for patients with persistent bacteremia linked to methicillin-resistant Staphylococcus aureus in COVID-19 cases. Founded in 2008, ContraFect aims to address the challenges posed by multi-drug resistant infections through its innovative treatments.

Vaxdyn specializes in the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. The company employs innovative technologies, including antigens, immunomodulators, nanoparticles, and monoclonal antibodies, to create effective vaccines that help mitigate the impact of these drug-resistant infections on public health. Vaxdyn addresses customer inquiries through various channels, including phone, email, and online applications, ensuring accessible communication regarding their offerings.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Amicrobe, Inc.​ is an advanced biomaterials company with innovative product candidates designed to prevent and treat infections. The Company’s new, synthetic block copolypeptides (A-Blocks) are engineered to provide broad antimicrobial activity and superior tissue coverage when our natural barriers of defense are broken in surgery, trauma / burns, and diabetic foot ulcers.

Institute for Molecular Bioscience is a research institute at The University of Queensland.

Microbion Corporation is a biopharmaceutical company focused on developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982 and headquartered in Bozeman, Montana, with an additional office in Vancouver, Canada, the company specializes in bismuth-thiols, which are designed to prevent microbial biofilms from forming on implanted medical devices and to manage biofilms in various infectious diseases. Microbion's product pipeline includes treatments for chronic and acute wound infections, particularly those related to diabetic foot ulcers, orthopedic implant-related infections, and other chronic wounds. The company also addresses the challenges posed by antibiotic-resistant microbes, including methicillin-resistant staphylococcus aureus, and aims to reduce infections associated with military wounds.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Module Innovations is a healthcare solutions provider focused on enhancing disease management for infectious diseases and antimicrobial resistance. The company has developed a portable and affordable point-of-care diagnostic platform that offers rapid, real-time information to improve clinical outcomes. Its initial products specifically target pathogens responsible for urinary tract infections (UTIs), such as E. coli, Klebsiella, Pseudomonas, and Enterococci, enabling quick pathogen identification and antibiotic susceptibility testing. Utilizing patented SDSAN technology, Module Innovations delivers UTI identification results in just 15 minutes and antibiotic susceptibility information within two hours. This innovative approach aims to facilitate informed decision-making for clinicians and provide faster outcomes for patients, making it a valuable tool in both clinical and home testing environments.

Peptilogics, Inc. is a biotechnology company based in West Mifflin, Pennsylvania, that focuses on developing novel peptide therapeutics to combat multidrug-resistant bacterial infections. Established in 2013, Peptilogics employs a unique computational platform that facilitates drug discovery by exploring new chemical design spaces and ensuring the biological viability and manufacturability of potential therapeutics. The company's lead candidate, PLG0206, is a broad-spectrum anti-infective peptide that has received FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation, targeting prosthetic joint infections, which represent a significant unmet medical need. Peptilogics aims to provide effective solutions to address the challenges posed by resistant bacteria and biofilms, ultimately improving treatment outcomes for patients.

Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.

Facile Therapeutics, Inc. is a biotechnology company based in Belmont, California, founded in 2017 by Marc Navre and Matthew Bogyo. The company focuses on developing therapeutic drugs for the treatment of Clostridium difficile (C diff) infections. Its lead product, Ebselen, is an anti-toxin that effectively targets C diff without harming healthy gut bacteria, thereby maintaining the natural resistance of the colon to reinfection. This innovative approach offers healthcare professionals an alternative treatment option that avoids the drawbacks associated with traditional antibiotics.

Pattern Bioscience, operating as Klaris Diagnostics, is a clinical diagnostics company focused on addressing antibiotic resistance. Founded in 2014 and based in Austin, Texas, the company has developed a next-generation clinical microbiology platform utilizing patented phenotypic single-cell technology. This innovative platform, known as Digital Culture technology, facilitates rapid pathogen identification and antibiotic susceptibility testing, providing results within hours rather than days. By integrating single-cell analysis with artificial intelligence pattern recognition, Pattern Bioscience bypasses traditional culture steps, leading to a more comprehensive and reliable diagnosis that encompasses all potential resistance mechanisms. This approach aims to enhance diagnostic accuracy and speed, significantly improving patient care in the face of growing concerns about antibiotic resistance.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

The University of Queensland (UQ), established in 1909 and located in Brisbane, Australia, is a prominent public research university known for its commitment to knowledge leadership and quality education. It consistently ranks among the world's top universities and has received more national teaching awards than any other Australian institution. UQ serves approximately 53,600 students across its three campuses, offering a wide range of degree programs, including associate, bachelor, master, and doctoral degrees. The university aims to empower its students to drive positive societal change through innovative research and teaching excellence.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Techulon, Inc. is a biotechnology company based in Blacksburg, Virginia, specializing in the development of treatments for drug-resistant infections. Founded in 2006, Techulon leverages genomic technology and cell-penetrating peptides to create innovative antibiotics. The company’s research focuses on novel peptide-peptide nucleic acids antimicrobial compounds that identify critical DNA sequences in microbes, enhancing treatment options for healthcare providers. Techulon operates from the Virginia Tech Corporate Research Center, where it also provides research laboratory services. The company’s efforts are supported by patents licensed from Virginia Tech, allowing for the development and commercialization of biopolymers with applications across research, therapeutics, energy, and sustainability.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Trellis Bioscience LLC is a biotechnology company focused on discovering and developing human antibody therapeutics for infectious diseases and oncology. The company utilizes its proprietary CellSpot technology platform to identify and extract rare, naturally optimized antibodies from healthy human donor blood cells. This enables the development of therapeutic monoclonal antibodies targeting various infectious diseases and cancer immune checkpoints. Trellis aims to offer alternatives for patients facing challenges with conventional protein therapeutics, particularly in cases where the immune system may attack these treatments. Founded in 1998, Trellis Bioscience is headquartered in Redwood City, California.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

TAXIS Pharmaceuticals, Inc. is a biopharmaceutical company based in Monmouth Junction, New Jersey, founded in 2009. The company is focused on developing innovative antibiotics to combat multidrug-resistant bacteria and the increasing threat of antimicrobial resistance. TAXIS Pharmaceuticals is working on several compounds, including TXA709, which is a prodrug that converts in the body to an active antibiotic agent, and TXA707, a benzamide derivative designed to disrupt the essential bacterial protein FtsZ, thereby inhibiting bacterial cell division. The company's approach emphasizes the discovery of novel mechanisms of action that differ from existing clinical options, leveraging its expertise in discovery chemistry to identify promising drug candidates.

Vaxxilon AG is a biotechnology company based near Basel, Switzerland, with research facilities in Berlin. The company specializes in the discovery and development of innovative synthetic carbohydrate vaccines aimed at preventing major infectious diseases. Vaxxilon's approach involves the design and production of homogeneous carbohydrate antigens combined with novel carrier molecules, allowing for the advancement of multiple vaccine candidates. Through its focused efforts, Vaxxilon seeks to create effective solutions for significant health challenges posed by infectious diseases.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Debiopharm Group is a biopharmaceutical development specialist based in Lausanne, Switzerland, focusing on in-licensing promising biologics and small molecule drug candidates for global registration. The group aims to maximize the commercial potential of its products through out-licensing agreements with pharmaceutical partners for sales and marketing. It operates multiple investment arms, including the Debiopharm Innovation Fund, which invests in early-stage companies within the biotechnology, diagnostics, and digital health sectors, focusing on smart data and biomarker development. This fund typically invests between $1 million and $10 million, seeking minority stakes and board representation in its portfolio companies. Additionally, Debiopharm Investment engages in private equity and real estate investments, targeting mature companies in IT security and renewable sectors, as well as residential and commercial properties primarily in Western Europe. With a commitment to long-term investments and active involvement in corporate governance, Debiopharm Group drives its portfolio companies toward successful market exits.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, that specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Founded in 2017, Idorsia focuses on various therapeutic areas, including central nervous system disorders, cardiovascular conditions, immunological issues, and orphan diseases. The company's clinical pipeline features treatments for conditions such as resistant hypertension, lupus, insomnia, cerebral vasospasm, and Fabry disease. Idorsia collaborates with several partners, including Janssen Biotech Inc. for the development of aprocitentan, ReveraGen for vamorolone in Duchenne muscular dystrophy, and Hoffman-La Roche for cancer immunotherapy compounds. Additionally, it works with Antares Pharma on a self-administered drug device for Selatogrel and with Neurocrine Biosciences on ACT-709478, currently in Phase 1 trials for epilepsy. With its strong scientific foundation, Idorsia aims to expand the horizon of therapeutic options available to patients.

ContraFect Corporation is a clinical-stage biotechnology firm based in Yonkers, New York, specializing in the development of therapeutic proteins and antibodies for the treatment of life-threatening, drug-resistant infectious diseases. The company's lead candidate, CF-301, is a novel lysin currently undergoing Phase III clinical trials for staphylococcus aureus bacteremia, including endocarditis. ContraFect is also advancing CF-296, an engineered lysin targeting invasive staphylococcal infections, and CF-370, an investigational therapy in preclinical stages aimed at treating infections caused by pseudomonas aeruginosa. The company has a research collaboration with The Rockefeller University to identify novel lysin candidates targeting gram-negative pathogens. Additionally, ContraFect has initiated an expanded access program for exebacase, intended for patients with persistent bacteremia linked to methicillin-resistant Staphylococcus aureus in COVID-19 cases. Founded in 2008, ContraFect aims to address the challenges posed by multi-drug resistant infections through its innovative treatments.

Recida Therapeutics is a biotechnology company focused on developing innovative antibiotic drugs to combat serious infections caused by antibiotic-resistant bacteria. The company's primary aim is to create novel-class antibiotics that specifically target multi-drug resistant gram-negative bacteria, which pose significant health risks to patients. By addressing the growing challenge of antibiotic resistance, Recida Therapeutics seeks to provide effective therapeutic options for individuals facing potentially life-threatening infections.

Spexis AG is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs and antibiotics to address severe or life-threatening diseases. Founded in 1996, the company focuses on addressing high unmet medical needs, particularly in the areas of antibiotic resistance and respiratory diseases. Spexis's lead product, murepavadin, is currently in Phase III development targeting Pseudomonas aeruginosa, a pathogen identified as a critical priority by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of innovative therapeutics in the respiratory domain.

ContraFect Corporation is a clinical-stage biotechnology firm based in Yonkers, New York, specializing in the development of therapeutic proteins and antibodies for the treatment of life-threatening, drug-resistant infectious diseases. The company's lead candidate, CF-301, is a novel lysin currently undergoing Phase III clinical trials for staphylococcus aureus bacteremia, including endocarditis. ContraFect is also advancing CF-296, an engineered lysin targeting invasive staphylococcal infections, and CF-370, an investigational therapy in preclinical stages aimed at treating infections caused by pseudomonas aeruginosa. The company has a research collaboration with The Rockefeller University to identify novel lysin candidates targeting gram-negative pathogens. Additionally, ContraFect has initiated an expanded access program for exebacase, intended for patients with persistent bacteremia linked to methicillin-resistant Staphylococcus aureus in COVID-19 cases. Founded in 2008, ContraFect aims to address the challenges posed by multi-drug resistant infections through its innovative treatments.

Forge Therapeutics, Inc. is a biotechnology company focused on discovering and developing innovative therapeutics through a unique chemistry platform that targets metalloproteins. The company specializes in creating novel antibiotics aimed at combating multi-drug resistant bacteria. By employing a proprietary approach that combines bioinorganic and medicinal chemistry, Forge develops selective small molecule inhibitors that target metalloenzymes, particularly in gram-negative bacteria. This strategy enables healthcare professionals to effectively access various biochemical processes and biological catalysis essential for treating challenging diseases.

SciBac Inc. develops innovative live biotherapeutics aimed at treating antibiotic-resistant diseases while strengthening the microbiome. Founded in 2015 and located in Milpitas, California, the company utilizes a patented MERGE platform that employs directed evolution to enhance the efficacy of beneficial microorganisms. SciBac's initial therapeutics focus on chronic infections associated with cystic fibrosis, targeting pathogens such as Pseudomonas, Staphylococcus, Burkholderia, and non-tuberculous mycobacteria (NTM). By safely transferring beneficial genetic traits, SciBac's approach aims to promote rapid recovery and minimize the risk of reinfections, thereby improving treatment outcomes for patients facing these challenging infections.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.

Bugworks Research Inc. is a biotechnology company focused on developing innovative antibiotics to combat antimicrobial resistance (AMR). Founded in 2014, the company operates from its headquarters in Saratoga, California, with additional offices in Adelaide, Australia, and Bengaluru, India. Bugworks specializes in creating a new class of antibiotic drugs designed to withstand drug resistance, offering products such as GYROX-1, an intravenous solution for critical care infections; GYROX-2, an oral treatment for various infections; and GYROX-3, specifically for cystic fibrosis patients. The company's research platform emphasizes broad-spectrum assets and leverages expertise in cancer biology and immunology to address the challenges posed by drug resistance in healthcare.

Talis Biomedical Corporation is focused on transforming diagnostic testing through the development and commercialization of innovative products aimed at enabling accurate, low-cost, and rapid molecular testing for infectious diseases at the point of care. Founded in 2010 and based in Menlo Park, California, with an additional office in Chicago, Talis is advancing its Talis One platform, a compact, sample-to-answer, cloud-enabled molecular diagnostic system. This platform is designed to facilitate point-of-care testing for various infectious diseases, including COVID-19, thereby improving accessibility and efficiency in healthcare settings such as senior care facilities and laboratories.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, that specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Founded in 2017, Idorsia focuses on various therapeutic areas, including central nervous system disorders, cardiovascular conditions, immunological issues, and orphan diseases. The company's clinical pipeline features treatments for conditions such as resistant hypertension, lupus, insomnia, cerebral vasospasm, and Fabry disease. Idorsia collaborates with several partners, including Janssen Biotech Inc. for the development of aprocitentan, ReveraGen for vamorolone in Duchenne muscular dystrophy, and Hoffman-La Roche for cancer immunotherapy compounds. Additionally, it works with Antares Pharma on a self-administered drug device for Selatogrel and with Neurocrine Biosciences on ACT-709478, currently in Phase 1 trials for epilepsy. With its strong scientific foundation, Idorsia aims to expand the horizon of therapeutic options available to patients.

Shionogi & Co Ltd is a pharmaceutical company that specializes in the manufacturing and distribution of both specialty and generic drugs, as well as diagnostic reagents and medical devices. The company is involved in various stages of drug development, including manufacturing, formulation, packaging, and analysis, which are integral to its commercialization research that extends from late-stage drug discovery to commercial production. Shionogi also emphasizes collaboration through partnerships and licensing agreements with academic institutions and venture companies to enhance its research and development efforts.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

Specific Diagnostics, LLC is a medical device company based in West Palm Beach, Florida, founded in 2011. The company specializes in developing solutions for the detection, identification, and antibiotic susceptibility testing of pathogens. Its flagship product, the Specific Reveal system, utilizes patented technology that incorporates a low-cost small molecule sensor. This system is designed to streamline workflows in clinical settings and accelerate the time required to obtain diagnostic results, ultimately enhancing patient care by providing timely and specific treatment options.

Curza Global, LLC is a therapeutics company focused on developing innovative drugs for infectious diseases and oncology. Founded in 2013 and headquartered in Salt Lake City, Utah, with an additional office in Cambridge, Massachusetts, Curza specializes in creating novel antibiotics to combat antibiotic-resistant bacteria, particularly targeting ESKAPE pathogens such as Enterococcus faecium, Staphylococcus aureus, and others. The company's lead program involves a new class of broad-spectrum antibiotics inspired by natural products, which aim to exploit previously unutilized sites on the bacterial ribosome. In addition to its antibiotic initiatives, Curza is also working on antibiofilm antibiotics that effectively target bacteria in biofilm forms and has oncology programs for cancer diagnosis. As antibiotic resistance continues to rise, Curza's developments address critical unmet medical needs within the pharmaceutical landscape.

Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing a diverse pipeline of novel biologic therapeutic candidates. The company employs advanced protein engineering techniques, including its proprietary sdAb platform, to target complex disease biology, with a focus on oncology, orphan diseases, and infectious diseases. Inhibrx's lead candidates include INBRX-109, a multivalent agonist in Phase 1 trials for solid tumors; INBRX-105, an antagonist of PD-L1 also in Phase 1 trials; INBRX-101, an Fc-fusion protein for alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting CD47. Additionally, the company is developing preclinical programs such as INBRX-106, an agonist of OX40, and INBRX-111, an antibody targeting Pseudomonas aeruginosa. Inhibrx has established collaborations with organizations like Celgene and Bluebird Bio and has received funding from various granting agencies, including the NIH and CARB-X.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.